DOP2023000280A - Inhibidores de cdk2 - Google Patents

Inhibidores de cdk2

Info

Publication number
DOP2023000280A
DOP2023000280A DO2023000280A DO2023000280A DOP2023000280A DO P2023000280 A DOP2023000280 A DO P2023000280A DO 2023000280 A DO2023000280 A DO 2023000280A DO 2023000280 A DO2023000280 A DO 2023000280A DO P2023000280 A DOP2023000280 A DO P2023000280A
Authority
DO
Dominican Republic
Prior art keywords
cdk2 inhibitors
cdk2
inhibitors
useful
pharmaceutically acceptable
Prior art date
Application number
DO2023000280A
Other languages
English (en)
Inventor
Vargas Richard
D Ramsden Philip
Bifulco Neil Jr
Brooijmans Natasja
Perola Emanuele
Mark Wenglowsky Steven
Wilson Douglas
L Kim Joseph
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of DOP2023000280A publication Critical patent/DOP2023000280A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona un compuesto representado por la Fórmula estructural (I): (I), o una sal farmacéuticamente aceptable de esta útiles para tratar el cáncer.
DO2023000280A 2021-06-28 2023-12-18 Inhibidores de cdk2 DOP2023000280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163215901P 2021-06-28 2021-06-28
PCT/US2022/035122 WO2023278326A1 (en) 2021-06-28 2022-06-27 Cdk2 inhibitors

Publications (1)

Publication Number Publication Date
DOP2023000280A true DOP2023000280A (es) 2024-03-28

Family

ID=82655170

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000280A DOP2023000280A (es) 2021-06-28 2023-12-18 Inhibidores de cdk2

Country Status (17)

Country Link
US (2) US11932648B2 (es)
EP (1) EP4363423A1 (es)
JP (1) JP2024524373A (es)
KR (1) KR20240046167A (es)
CN (1) CN117897384A (es)
AR (1) AR126251A1 (es)
AU (1) AU2022301047A1 (es)
CA (1) CA3223223A1 (es)
CO (1) CO2024000237A2 (es)
CR (1) CR20230598A (es)
DO (1) DOP2023000280A (es)
EC (1) ECSP24006831A (es)
IL (1) IL309118A (es)
MX (1) MX2024000230A (es)
TW (1) TW202317574A (es)
UY (1) UY39832A (es)
WO (1) WO2023278326A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
CR20230598A (es) 2021-06-28 2024-04-25 Blueprint Medicines Corp Inhibidores de cdk2
WO2024148087A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
WO2024148083A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Solid forms of a cdk2 inhibitor
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
WO2024148091A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
WO2024168298A1 (en) 2023-02-10 2024-08-15 Blueprint Medicines Corporation The cdk2 inhibitor blu-222 for treatment of cancer
WO2024171094A1 (en) 2023-02-17 2024-08-22 Novartis Ag Cyclin-dependent kinase (cdk2) inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113574A (pt) 2000-08-31 2003-07-22 Pfizer Prod Inc Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
KR100909665B1 (ko) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
AU2005205118B2 (en) 2004-01-09 2009-02-26 Novartis Ag Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
US8362031B2 (en) 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2006283592A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
KR20160007577A (ko) 2013-05-10 2016-01-20 카루스 떼라퓨틱스 리미티드 신규한 히스톤 디아세틸라제 억제제들
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
MY190459A (en) 2015-06-04 2022-04-21 Aurigene Discovery Tech Ltd Substituted heterocyclyl derivatives as cdk inhibitors
US11459308B2 (en) 2016-12-05 2022-10-04 Microbiotix, Inc. Broad spectrum inhibitors of filoviruses
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CN111601804B (zh) 2018-11-27 2024-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
KR20210099611A (ko) 2018-11-30 2021-08-12 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도
AU2020213761C1 (en) 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CA3143525A1 (en) 2019-06-28 2020-12-30 Gb002, Inc. Heterocyclic kinase inhibitors and products and uses thereof
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
WO2022061155A1 (en) 2020-09-17 2022-03-24 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
US20240261297A1 (en) 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment
MX2023015245A (es) 2021-06-16 2024-01-19 Blueprint Medicines Corp Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CR20230598A (es) 2021-06-28 2024-04-25 Blueprint Medicines Corp Inhibidores de cdk2
WO2023092088A1 (en) 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same

Also Published As

Publication number Publication date
IL309118A (en) 2024-02-01
CR20230598A (es) 2024-04-25
US11970498B2 (en) 2024-04-30
ECSP24006831A (es) 2024-07-31
CA3223223A1 (en) 2023-01-05
TW202317574A (zh) 2023-05-01
AR126251A1 (es) 2023-10-04
EP4363423A1 (en) 2024-05-08
CN117897384A (zh) 2024-04-16
KR20240046167A (ko) 2024-04-08
US20230159535A1 (en) 2023-05-25
JP2024524373A (ja) 2024-07-05
AU2022301047A1 (en) 2024-01-04
MX2024000230A (es) 2024-04-01
WO2023278326A1 (en) 2023-01-05
UY39832A (es) 2023-01-31
CO2024000237A2 (es) 2024-02-05
US11932648B2 (en) 2024-03-19
US20230322791A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
DOP2023000280A (es) Inhibidores de cdk2
CO2022010317A2 (es) Inhibidores de egfr
CO2021016504A2 (es) Inhibidores de cdk
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
CR11099A (es) Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2024009571A2 (es) Inhibidores de parp1
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
UY39662A (es) Inhibidores de egfr
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
NI200700323A (es) 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
CO6382120A2 (es) Compuestos ciclopropilo
AR128017A1 (es) Compuestos de pirazolopirazina como inhibidores de shp2
AR129088A1 (es) INHIBIDORES DE PI3Ka
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7
CO2022010019A2 (es) Composiciones de ixabepilona
AR119557A1 (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer